Long-Term Fosfomycin-Tromethamine Oral Therapy for Difficult-To-Treat Chronic Bacterial Prostatitis

Antimicrob Agents Chemother. 2015 Dec 14;60(3):1854-8. doi: 10.1128/AAC.02611-15.

Abstract

This is a retrospective study of 15 difficult-to-treat (i.e., exhibiting previous failure, patient side effects, or resistance to ciprofloxacin and co-trimoxazole) chronic bacterial prostatitis infections (5 patients with multidrug-resistant Enterobacteriaceae [MDRE]) receiving fosfomycin-tromethamine at a dose of 3 g per 48 to 72 h for 6 weeks. After a median follow-up of 20 months, 7 patients (47%) had a clinical response, and 8 patients (53%) had persistent microbiological eradication; 4/5 patients with MDRE isolates achieved eradication. There were no side effects. Fosfomycin-tromethamine is a possible alternative therapy for chronic bacterial prostatitis.

MeSH terms

  • Adult
  • Aged
  • Aged, 80 and over
  • Anti-Bacterial Agents / therapeutic use*
  • Ciprofloxacin / therapeutic use*
  • Drug Resistance, Multiple, Bacterial*
  • Fosfomycin / therapeutic use*
  • Humans
  • Male
  • Microbial Sensitivity Tests
  • Middle Aged
  • Prostatitis / drug therapy*
  • Prostatitis / microbiology
  • Retrospective Studies
  • Trimethoprim, Sulfamethoxazole Drug Combination / therapeutic use*
  • Tromethamine
  • Young Adult

Substances

  • Anti-Bacterial Agents
  • Tromethamine
  • Fosfomycin
  • Ciprofloxacin
  • Trimethoprim, Sulfamethoxazole Drug Combination

Grants and funding

This research received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors.